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Prevalence of cervical disease at age 20 after immunisation 
with bivalent HPV vaccine at age 12-13 in Scotland: retrospective 
 population study
Tim Palmer,1 Lynn Wallace,2 Kevin G Pollock,3,4 Kate Cuschieri,5 Chris Robertson,3,6,7  
Kim Kavanagh,7 Margaret Cruickshank8
ABSTRACT 
OBJECTIVE
To quantify the effect on cervical disease at age 
20 years of immunisation with bivalent human 
papillomavirus (HPV) vaccine at age 12-13 years.
DESIGN
Retrospective population study, 1988-96.
SETTING
National vaccination and cervical screening 
programmes in Scotland.
PARTICIPANTS
138 692 women born between 1 January 1988 and 5 
June 1996 and who had a smear test result recorded 
at age 20.
MAIN OUTCOME MEASURES
Effect of vaccination on cytology results and 
associated histological diagnoses from first year of 
screening (while aged 20), calculated using logistic 
regression.
RESULTS
138 692 records were retrieved. Compared with 
unvaccinated women born in 1988, vaccinated women 
born in 1995 and 1996 showed an 89% reduction 
(95% confidence interval 81% to 94%) in prevalent 
cervical intraepithelial neoplasia (CIN) grade 3 or 
worse (from 0.59% (0.48% to 0.71%) to 0.06% 
(0.04% to 0.11%)), an 88% reduction (83% to 92%) 
in CIN grade 2 or worse (from 1.44% (1.28% to 1.63%) 
to 0.17% (0.12% to 0.24%)), and a 79% reduction 
(69% to 86%) in CIN grade 1 (from 0.69% (0.58% to 
0.63%) to 0.15% (0.10% to 0.21%)). Younger age at 
immunisation was associated with increasing vaccine 
effectiveness: 86% (75% to 92%) for CIN grade 3 or 
worse for women vaccinated at age 12-13 compared 
with 51% (28% to 66%) for women vaccinated at age 
17. Evidence of herd protection against high grade 
cervical disease was found in unvaccinated girls in the 
1995 and 1996 cohorts.
CONCLUSIONS
Routine vaccination of girls aged 12-13 years with the 
bivalent HPV vaccine in Scotland has led to a dramatic 
reduction in preinvasive cervical disease. Evidence 
of clinically relevant herd protection is apparent in 
unvaccinated women. These data are consistent 
with the reduced prevalence of high risk HPV in 
Scotland. The bivalent vaccine is confirmed as being 
highly effective vaccine and should greatly reduce 
the incidence of cervical cancer. The findings will 
need to be considered by cervical cancer prevention 
programmes worldwide.
Introduction
Cervical carcinoma is the fourth most common 
cancer in women and a major cause of morbidity 
and mortality worldwide.1 In developed countries 
where organised cervical screening programmes have 
been implemented, the incidence and mortality from 
cervical cancer has decreased, although in many there 
is either no further diminution or even an increase 
in incidence. Many factors might contribute to these 
trends, including decreased uptake of screening, 
increased rates of human papillomavirus (HPV) 
infection, and changes in sexual behaviour.2 3 Middle 
and lower income countries mostly do not have 
the resources to support organised screening, and 
cervical cancer remains a considerable problem. The 
development of vaccines against the most important 
oncogenic HPV types has the potential to be a major 
step in the prevention of cervical cancer.
In 2008, Scotland introduced a national 
immunisation programme against HPV using the 
bivalent vaccine, which was used until 2012. The 
immunisation programme was school based, targeted 
girls aged 12 and 13 (routine vaccination), and was 
supplemented with a three year catch-up programme 
to age 18. Uptake in the catch-up cohort was about 
65% overall, but uptake in the routinely immunised 
cohorts has consistently exceeded 85%.4 5
Up to and including 5 June 2016, women in 
Scotland were invited for cervical screening at age 
20. Thereafter, they are screened from age 25. Women 
from the catch-up cohorts have been screened since 
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2010 and women from the routinely immunised 
cohorts have been screened since 2015. Scotland has 
comprehensive cervical screening data that contain 
a woman’s entire screening record, immunisation 
status, and unique personal identifier (community 
health index (CHI) number). We have been able to 
show the effectiveness of immunisation on various 
outcomes, including HPV prevalence, herd immunity, 
cervical disease, colposcopy outcomes, and uptake of 
cervical screening. This constitutes a comprehensive 
programme of immunisation surveillance.6-12
Recently we reported on the effect of the bivalent 
HPV vaccine on prevalence of HPV types in women 
who were immunised at age 12-13 years and attended 
for screening at age 20.12 In the 1995 birth cohort 
(associated with 90% uptake of vaccine at age 13) a 
virtual eradication of infection related to HPV types 
16 and 18 and a statistically significant reduction in 
cross protective types was observed. Furthermore, 
no evidence of replacement by other HPV types was 
evident and statistically significant herd protection 
in unvaccinated women was identified. Similar 
reductions have been reported in the Netherlands, 
where the bivalent vaccine is used.13 The considerable 
reduction in the most carcinogenic HPV types clearly 
has implications for associated disease and the way it 
is managed clinically.
In the present study, we report at a national, 
programme level and through linkage to screening 
records the effect of routine immunisation of girls aged 
12-13 years with the bivalent HPV vaccine on levels of 
cytological abnormalities and cervical intraepithelial 
neoplasia (CIN). These findings supplement previous 
studies in Scotland and the Netherlands, which 
indicate that the bivalent vaccine will afford protection 
against most HPV related cervical cancers.
Methods
Scottish cervical screening programme
Scotland has an organised, national cervical screening 
programme, which achieves about 70% uptake.14 Up 
to and including 5 June 2016 women aged between 20 
and 60 were eligible for screening and thereafter the 
age range changed to between 25 and 64, 364 days 
in line with the rest of the United Kingdom. Eligible 
women are screened every three years until age 50 
and then every five years until age 65. Screening is 
extended for a further five years if needed to complete 
follow-up of screen detected abnormalities. Scotland 
uses Thinprep liquid based cytology with image 
assisted screening (ThinPrep Imaging System; Hologic, 
Marlborough, MA). Eight National Health Service 
cytology laboratories served the programme during 
the period reported and processed around 400 000 
samples a year. Cytological and histological findings 
are classified according to British Association for 
Cytopathology and NHS cervical screening programme 
criteria.15 16 Table 1 compares the three commonly 
used reporting systems.
Women are referred for colposcopy after one 
finding of high grade dyskaryosis or ASCH (atypical 
squamous cells, cannot rule out high grade squamous 
intraepithelial lesion), two findings of low grade 
dyskaryosis or three findings of borderline change 
during an episode of abnormal follow-up, or three 
abnormal results in the past 10 years. Women with 
low grade dyskaryosis or borderline changes are 
followed up with cytology at six months if not referred 
for colposcopy. Smear tests are repeated within three 
months if results are unsatisfactory, and women with 
three consecutive unsatisfactory results are referred for 
colposcopy. Ablation or excision is routinely carried out 
for CIN grade 2 or worse. Conservative management is 
the expected treatment for low grade disease. Scotland 
does not use HPV testing for the triage of low grade 
cytology.
Data extraction, annotation, and exclusions
The Scottish Cervical Call-Recall System (SCCRS) is a 
national IT system, which contains comprehensive 
data relating to screening and acts as an active 
management tool. We interrogated SCCRS for screening 
data on all women born between 1 January 1988 and 5 
June 1996 from the date of first eligibility for screening 
(age 20) to the date of data extraction (August 2017). 
Data extracted included CHI number, postcode of 
residence, date of birth, attendance, immunisation 
status, cytology result, colposcopy referral, and related 
histological diagnosis. The postcode of residence 
was used to derive the Scottish index of multiple 
deprivation fifth (where the first fifth represents the 
most deprived), and rurality index (derived from the 
Scottish government eight level indicator, with three 
levels: urban, accessible rural (30-60 minute drive 
to a settlement of ≥10 000), and remote rural (>60 
minute drive to a settlement of ≥10 000)). Duplicate 
records for a woman are linked in SCCRS under the 
most recent CHI number, and personal data (including 
postcode) are updated daily from the Scottish national 
population register used throughout the Scottish 
school and healthcare systems.
For all cohorts we restricted the data to those who 
had cytology tests and colposcopy appointments at age 
20. The results for most women corresponded to their 
first smear test or first colposcopy examination; for the 
few women with more than one smear test or biopsy in 
their first year of screening, we used the most severe 
result. We excluded records without a deprivation 
and rurality score from analysis. Although data on 
all screening events were extracted, for this analysis 
we only used data on attendance in the first year of 
eligibility, minimising bias resulting from differences 
in age at time of screening and opportunity for disease 
detection. Age at immunisation was calculated based 
on age at first vaccination. Figure 1 shows the relation 
between immunisation, year of first screen, and data 
extraction.
Measures of effect and outcomes
Cytology was recorded as negative (no evidence of 
disease), borderline (including borderline glandular 
changes), and low, moderate, or severe grade 
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dyskaryosis (including glandular abnormalities). 
Histology was coded as normal (no CIN detected), 
CIN grade 1, CIN grade 2, and CIN grade 3 or worse 
(glandular neoplasia or cancer). We categorised 
women not referred for colposcopy as having no CIN 
detected. Wilson’s method was used to calculate the 
confidence intervals for the percentages of women in 
the outcome groups. We used multivariate multinomial 
logistic regression models to explore the associations 
between cytology results, referral for colposcopy 
and histological diagnosis, and immunisation and 
demographic variables. Odds ratios for the cytological 
and histological outcomes are reported with 95% 
confidence intervals. Vaccine effectiveness for three 
doses compared with no doses was calculated as 
100×(1−odds ratio), and for those fully vaccinated 
we estimated vaccine effectiveness separately by age 
at vaccination with reference to unvaccinated women 
in the pre-immunisation cohorts (born 1988-90). We 
used interaction tests to determine if the trend over 
time was the same between fully vaccinated and 
unvaccinated women. In addition to the number of 
doses of vaccine, we investigated the influence of birth 
cohort, Scottish index of multiple deprivation fifth, 
and the urban rural indicator on vaccine effectiveness. 
The pre-immunisation cohorts (born 1988-90) acted 
as the comparator group, although a small proportion 
of women born in 1990 were eligible for immunisation. 
Girls in the catch-up group (1991-94) are more likely 
to have been exposed to HPV before immunisation, 
whereas the routinely immunised group (1995-96) are 
considered more likely to be HPV naïve. We investigated 
Table 1 | Comparison of reporting systems used to classify cervical cytology
NHS cervical screening programme15 Two tier Bethesda system17
Borderline squamous and glandular  
changes without human papillomavirus 
(HPV) Low grade
ASCUS (atypical squamous cells of undetermined significance), ASCH (atypical 
squamous cells, cannot rule out high grade squamous intraepithelial lesion), or 
AGUS (atypical glandular cells of undetermined significance)
HPV changes (koilocytosis) with or without 
low grade dyskaryosis LSIL (low grade squamous intraepithelial lesion)
High grade dyskaryosis (moderate)
High grade
HSIL (high grade squamous intraepithelial lesion)High grade dyskaryosis (severe)
High grade dyskaryosis (?invasive) Cancer
Glandular neoplasia AGC (atypical glandular cells), favour neoplasiaAIS (adenocarcinoma in situ)/adenocarcinoma
First invitation for screening at age 20
Routine immunisation at age 12-13 years
Catch-up immunisation over two years
2008
Year of birth:
age (years) at
vaccination
Year
2009 2010 2011 2012 2013 2014 2015 2016 2017
1996:
12-13
1995:
12-13
1994:
14-15
1993:
15-16
1992:
16-17
1991:
17-18
1990:
≥18
1989:
no vaccine
1988:
no vaccine
Fig 1 | Schedule of immunisation, screening, and data collection. Only a few birth years in the 1990s were eligible. 
Girls born in 1994 not covered in first year of catch-up and immunised either side of 15th birthday, depending on date 
of birth. For first invitation to screening at age 20, women born in 1996 only eligible if date of birth was before 6 June. 
Data collated for all screening related events in first year of screening. Women born in 1996 had at least 15 months 
between initial invitation to screening and data extraction
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herd protection by comparing the disease rates among 
unvaccinated women in the 1991-92, 1993-4, and 
1995-96 cohorts with unvaccinated women in the 
1989-90 cohort. The statistical analysis was carried 
out in R version 3.5.1 and SPSS version 21.
Patient and public involvement
There was no patient or public involvement in the 
design or analysis of this study. The records were 
anonymised before analysis, with preservation of 
linkage between immunisation, cytology, and histology 
when appropriate. Caldicott Guardian approval, a 
UK process to ensure that the use of personal data 
complies with legal requirements for data protection 
and is in the public interest, was obtained for the use 
of data. The data were generated through the routine 
activity of the Scottish cervical screening programme. 
Participation in the programme gives implied consent 
for the use of data derived from this participation for 
service monitoring and improvement. Management of 
individual patients is not affected by this study, and 
no individuals can be identified from the anonymised 
dataset used by the researchers.
Results
In total, 138 692 women born between 1 January 1988 
and 5 June 1996 had a smear test result recorded at 
age 20. Table 2 and supplementary table 1 show 
the distribution of the records by year of birth and 
immunisation status. Three groups are identified, 
broadly corresponding to unvaccinated women (born 
1988-90, age 18-20 in 2008), women vaccinated 
during the catch-up programme (born 1991-94, 
age 14-17 at vaccination), and women routinely 
vaccinated (born 1995-96, age 12-13 at vaccination). 
Cumulatively within the extract, 64 026 women were 
unvaccinated and 68 480 had three doses of vaccine 
(fully vaccinated). Only 2051 women received one dose 
and 4135 women received two doses. The number of 
women born in 1996 in the dataset is less than in other 
years as only those born before 6 June were eligible for 
screening because of changes to the age range for the 
screening programme. The number of women who had 
their first dose at age 14 is lower than in other years 
because of the phasing of the catch-up programme 
(fig 1).
Tables 3 and 4 show the adjusted odds ratios 
for cytological and histological outcomes by 
immunisation status and age at which the first dose 
was administered and by year of birth in unvaccinated 
women, respectively. Figures 2 and 3 show the trends in 
cytological abnormalities and histologically confirmed 
CIN by percentage of the screened population stratified 
by no or complete immunisation.
Cytological outcomes
The overall rate of severe dyskaryosis or worse 
decreased from 0.75% (0.63% to 0.89%) for women 
born in 1988 to 0.06% (0.04% to 0.11%) for 
women born in 1995-96, and moderate dyskaryosis 
decreased from 1.18% (1.04% to 1.36%) to 0.27% 
(0.21% to 0.35%), representing reductions of 92% 
(85% to 95%) and 77% (69% to 83%), respectively 
(table 2). Rates of severe and moderate dyskaryosis 
in unvaccinated compared with fully vaccinated 
women born in 1995 and 1996 were not significantly 
different (fig 2). Overall, borderline/ASCUS rates 
declined by 34% (30% to 39%), with a similar trend 
over the cohort in vaccinated and unvaccinated 
women (interaction test P=0.11), although the 
rate was lower in vaccinated women (15%, 11% to 
19%). The reporting of low grade dyskaryosis/LSIL 
increased during the period of observation. The 
trend with birth cohort was the same for vaccinated 
and unvaccinated women (interaction test P=0.17); 
vaccinated women had 19% (14% to 24%) lower 
rates (table 2 and fig 2).
Vaccine effectiveness in fully immunised 
women, vaccinated at ages 12-13, compared with 
unvaccinated women in 1988-90 was 42% (38% to 
46%) for borderline/ASCUS, −38% (−48% to−28%) 
for low grade dyskaryosis/LSIL, 80% (72% to 86%) for 
moderate dyskaryosis/HSIL-M, and 93% (86% to 97%) 
for high grade dyskaryosis/HSIL-H (table 3).
Histological outcomes
High grade CIN showed a significant overall decline 
(table 2 and fig 2). The rates of CIN grade 3 or 
worse decreased by 89% (81% to 94%), from a pre-
immunisation rate of 0.59% (0.48% to 0.71%) in 
women born in 1988, to 0.06% (0.04% to 0.11%) 
in women born in 1995-96. CIN grade 2 or worse 
decreased by 88% (83% to 92%), from a pre-
immunisation rate of 1.44% (1.28% to 1.63), to 0.17% 
(0.12% to 0.24%) in women born in 1995-96. No 
CIN grade 2 or worse (upper confidence limit 0.7%) 
was found in unvaccinated women in this age group 
(n=545). The decline in high grade CIN was steeper in 
fully vaccinated women (P=0.005 interaction test), but 
by the 1995-96 cohort, rates of high grade CIN were 
not significantly different between unvaccinated and 
vaccinated women (P=0.47) (fig 3).
CIN grade 1 decreased from 0.69% (0.58% to 
0.63%) of women before immunisation (1988 cohort) 
to 0.15% (0.10% to 0.21%) overall for women born 
in 1995-96: a 79% (69% to 86%) reduction (table 
2). The trend over birth cohort was the same for fully 
immunised and unimmunised women (interaction 
test P=0.90), and there was no evidence that the rates 
differed between fully immunised and unimmunised 
women (P=0.17; fig 3).
For fully immunised women, first vaccinated at age 
12-13, vaccine effectiveness for CIN grade 1 was 78% 
(66% to 86%), for CIN grade 2 was 89% (81% to 94%), 
and for CIN grade 3 or worse was 86% (75% to 92%), 
compared with unvaccinated women in the 1988-90 
cohorts. Vaccine effectiveness was lower for women 
first vaccinated at age 17: 41% (14% to 59%) for CIN 
grade 1, 56% (35% to 70%) for CIN grade 2, and 45% 
(17% to 64%) for CIN grade 3 or worse (table 3).
Herd protection was observed for the unvaccinated 
women in the 1995-96 cohort, with a 63% reduction in 
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the odds of CIN grade1 (11% to 85%), 67% reduction 
for CIN grade 2 (19% to 86%), and 100% (69% to 
100%) reduction for CIN grade 3, compared with 
unvaccinated women in 1988-90. Similar reductions 
were noted for moderate dyskaryosis/HSIL-M (58%, 
21% to 78%) and high grade dyskaryosis/HSIL-H 
(85%, 38% to 96%) but not for borderline/ASCUS or 
low grade dyskaryosis/LSIL (table 4).
One and two dose outcomes
Tables 2 and 3 show the number of women with 
one dose or two doses of vaccine and outcomes. 
Although reductions occurred in both cytological and 
histological outcomes with two doses, no statistically 
significant effect was seen for either one dose or two 
doses. The numbers were too small to allow analysis 
by year of birth.
Table 2 | Number (percentage) of records in data extract stratified by year of birth, number of doses of bivalent human papillomavirus vaccine, 
cytological abnormality, referral for colposcopy, and histological diagnosis
Variables
Year of birth
Total1988 1989 1990 1991 1992 1993 1994 1995 1996
No of records 17 589 16 801 17 471 17 618 16 669 16 050 15 854 15 229 5414 138 692
Vaccine doses:
 0 17 579  (99.9)
16 731  
(99.6)
14 038  
(80.4)
4994  
(28.3)
3002  
(20.3)
3283  
(20.3)
2209  
(13.9)
1665
(10.9)
545  
(10.1)
64 026  
(46.2)
 1 3 (0.02) 22 (0.1) 233 (1.4) 538 (3.1) 415 (2.5) 437 (2.7) 267 (1.7) 101 (0.7) 29 (0.5) 2051 (1.5)
 2 2 (0.01) 18 (0.1) 488 (2.8) 1196 (6.8) 815 (5.1) 833 (5.2) 548 (3.5) 161 (1.1) 38 (0.7) 4135 (3.0)
 3 5 (0.03) 30 (0 2) 2706 (15.5) 10 890  (61.8)
12 401  
(74.4)
11 517  
(71.8)
12 830  
(80.9)
13 229  
(87.3)
4802  
(88.7)
68 480  
(49.4)
Cytology result:
 Negative 14 500  (82.4)
13 923  
(82.9)
14 302  
(81.9)
14 780  
(83.9)
14 031  
(84.2)
13 640  
(85.0)
13 452  
(84.8)
13 080  
(85.9)
4656  
(86.0)
116 364  
(83.9)
 Borderline/ASCUS 1819  (10.3)
1828  
(10.9)
2102  
(12.0)
1939  
(11.0)
1624  
(9.8)
1143  
(7.1)
1112  
(7.0)
1034  
(6.8)
365  
(6.7)
12 966  
(9.3)
  Low grade dyskaryosis/LSIL 929 (5.3) 779 (4.6) 786 (4.5) 694 (3.9) 869 (5.2) 1111 (6.9 1178 (7.4) 1061 (7.0) 375 (6.9) 7782 (5.6)
 HSIL-M 208 (1.2) 176 (1.0) 191 (1.1) 137 (0.8) 93 (0.6) 102 (0.6) 76 (0.5) 43 (0.3) 13 (0.2) 1040 (0.7)
 HSIL-S+ 132 (0.8) 95 (0.6) 90 (0.5) 68 (0.4) 52 (0.3) 54 (0.4) 36 (0.2) 8 (0.1) 5 (0.1) 540 (0.4)
Referral for colposcopy 680 (3.9) 612 (3.6) 557 (3.2) 434 (2.5) 355 (2.1) 295 (1.9) 278 (1.7) 120 (0.8) 20 (0.4) 3351 (2.4)
Histological diagnosis:
 CIN grade 1 122 (0.7) 102 (0.6) 98 (0.6) 76 (0.4) 63 (0.4) 60 (0.4) 45 (0.3) 26 (0.2) 4 (0.1) 596 ( .4)
 CIN grade 2 151 (0.9) 118 (0.7) 106 (0.6) 75 (0.4) 64 (0.4) 63 (0.4) 38 (0.2) 20 (0.1) 2 (0.04) 637 (0.5)
  CIN grade 3 or worse 103 (0.6) 81 (0.5) 86 (0.5) 66 (0.4) 53 (0.3) 38 (0.2) 29 (0.2) 9 (0.1) 4 (0.1) 469 (0.3)
ASCUS=atypical squamous cells of undetermined significance; LSIL=low grade squamous intraepithelial lesion; HSIL=high grade squamous intraepithelial lesion (HSIL-M=mild dyskaryosis; HSIL-
S+=severe dyskaryosis); CIN=cervical intraepithelial neoplasia.
Table 3 | Cytological and histological abnormalities at age 20 by age at first dose of bivalent human papillomavirus vaccine and immunisation status. 
Values are adjusted odds ratios (95% confidence intervals) unless stated otherwise
Age groups 
and dose
Years to first 
screen No
Borderline 
changes
Low grade 
dyskaryosis
High grade dyskaryosis CIN grade
Moderate Severe 1 2 3 or worse
All: 1 dose 2051 0.94  (0.81 to 1.08)
1.27  
(1.05 to 1.53)
0.89  
(0.58 to 1.37)
1.02  
(0.59 to 1.75)
0.94  
(0.53 to 1.68)
0.95  
(0.56 to 1.59)
1.19 
(0.70 to 2.05)
All: 2 doses 4135 0.94  (0.85 to 1.04)
1.09  
(0.94 to 1.26)
0.91  
(0.67 to 1.24)
0.62  
(0.38 to 1.00)
0.70 | 
(0.43 to 1.12)
0.70 
(0.45 to 1.07)
0.77  
(0.48 to 1.24)
3 doses:
 12 and 13 7 or 8 16 200 0.58  (0.54 to 0.62)
1.38  
(1.28 to 1.48)
0.20  
(0.15 to 0.28)
0.07  
(0.03 to 0.14) 0.22 ( .14 to 0.34)
0.11  
(0.06 to 0.19)
0.14  
(0.08 to 0.25)
 14 6 5409 0.55  (0.50 to 0.62)
1.37  
(1.22 to 1.53)
0.26  
(0.16 to 0.42)
0.23  
(0.11 to 0.46)
0.48  
(0.29 to 0.79)
0.13  
(0.05 to 0.31)
0.18  
(0.07 to 0.43)
 15 5 16 532 0.59  (0.55 to 0.63)
1.31  
(1.22 to 1
41)
0.36  
(0.28 to 0.47)
0.28  
(0.20 to 0.41)
0.48  
(0.36 to 0.65)
0.35  
(0.25 to 0.48)
0.29  
(0.19 to 0.44)
 16 4 17 511 0.75  (0.71 to 0.80)
1.05  
(0.97 to 1.13)
0.35  
(0.27 to 0.45)
0.25  
(0.17 to 0.37)
0.58  
(0.44 to 0.77)
0.31  
(0.23 to 0.44)
0.27  
(0.18 to 0
41)
 17 3 8711 0.86  (0.80 to 0.93)
0.77  
(0.96 to 0.86)
0.60  
(0.46 to 0.78)
0.42  
(0.27 to 0.63)
0.59  
(0.41 to 0.86)
0.45  
(0.30 to 0.66)
0.55  
(0.36 to 0.83)
 ≥18 2 4117 0.98  (0.89 to 1.08)
0.80  
(0.68 to 0.94)
0.65  
(0.45 to 0.93)
0.88  
(0.58 to 1.35)
0.79 
(0.50 to 1.25)
0.75  
(0.48 to 1.15)
0.85 
(0.52 to 1.37)
≥1991: 0 doses 15678 0.89  (0.84 to 0.94)
1.41  
(1.31 to 1.52)
0.84  
(0.70 to 1.01)
0.90  
(0.71 to 1.14)
0.62  
(0.47 to 0.82)
0.81  
(0.65 to 1.02)
0.82  
(0.63 to 1.07)
1988-90: 0 
doses 48 348 1.00 1.00 1 00 1.00 1.00 1.00 1.00
CIN=cervical intraepithelial neoplasia.
Estimates derived from multinomial regression model adjusting also for deprivation and rurality. Estimated effects of these variables were similar to those in supplementary table 1 and are not 
repeated here.
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Discussion
This study reports statistically significant reductions 
in all grades of cervical intraepithelial neoplasia 
(CIN), equating to vaccine effectiveness estimates of 
80% or greater after routine immunisation at age 12-
13 years. The prevalence of high grade dyskaryosis 
was similarly reduced. Herd protection has been 
shown in unvaccinated women in the cohort offered 
routine immunisation. The changes in cytological 
abnormality and histologically confirmed cervical 
disease in women attending for their first cervical 
screen aged 20 associated with routine vaccination 
at age 12-13 years with the bivalent human 
papillomavirus (HPV) vaccine in a setting that offered 
both a catch-up programme and that achieved high 
and consistent uptake. The results of this study were 
derived from data that directly link immunisation 
status and screening outcome at the level of the 
individual. We are confident that the reduction in 
disease does not relate to the inability of cytological 
screening to detect disease in vaccinated women, 
given previous data on cytology performance that 
showed no loss of sensitivity in vaccinated compared 
with unvaccinated women, and the deterioration in 
the clinical significance or positive predictive value 
of cytologically defined low grade disease described 
elsewhere.5
The increase in reporting of low grade dyskaryosis/
LSIL in immunised women was statistically significant, 
in contrast with the reduction in all other cytological 
categories and all grades of CIN. Scottish surveillance 
data indicate that vaccine types and cross protected 
Table 4 | Cytological and histological abnormalities at age 20 in women who did not receive bivalent human papillomavirus vaccine, by year of birth. 
Values are adjusted odds ratios (95% confidence intervals) unless stated otherwise
Year of 
birth: age 
(years)
No of 
women
Borderline 
changes
Low grade 
 dyskaryosis
High grade dyskaryosis CIN grade
Moderate Severe 1 2 3 or worse
1995-96: 
12-13 2210 0.64 (0.55 to 0.76) 1.62 (1.38 to 1.90) 0.42 (0.23 to 0.79) 0.15 (0.04 to 0.62) 0.37 (0.15 to 0.89) 0.34 (0.14 to 0.81) 0.00 (0.00 to 0.31*)
1993-94:  
14 or 15 5472 0.75 (0.68 to 0.83) 1.70 (1.53 to 1.89) 0.81 (0.60 to 1.08) 1.11 (0.79 to 1.56) 0.53 (0.33 to 0.86) 0.78 (0.54 to 1.13) 0.76 (0.49 to 1.18)
1991-92:  
16 or 17 7996 1.05 (0.97 to 1.13) 1.16 (1.04 to 1.28) 0.98 (0.78 to 1.23) 0.95 (0.70 to 1.28) 0.74 (0.53 o 1.05 0.97 (0.73 to 1.29) 1.07 (0.78 to 1.47)
1988-90: 
≥18 48 348 1.00 1.00 1.00 1.00 1.00 1.00 1.00
CIN=cervical intraepithelial neoplasia.
Estimates derived from multinomial regression model, adjusted for deprivation and rurality using data only from unvaccinated women. 1988-90 cohorts were not eligible for vaccine.
*Estimate based on Fisher’s exact test.
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Fig 2 | Cytological abnormality (% of women screened) by year of birth and immunisation status. 1988-90=pre-immunisation programme cohort; 
1991-94=catch-up cohort; 1995-96=routinely immunised cohort. Whiskers represent 95% confidence intervals. ASCUS=atypical squamous cells 
of undetermined significance; LSIL=low grade squamous intraepithelial lesion; HSIL=high grade squamous intraepithelial lesion (HSIL-M=mild 
dyskaryosis; HSIL-S+=severe dyskaryosis)
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types (HPV 16, 18, 31, 33, and 45) are found in a 
higher proportion of samples with borderline/ASCUS 
cytology than in samples with low grade dyskaryosis/
LSIL cytology and this could, in part, explain this 
observation. The human papillomavirus (HPV) 
types that remain after immunisation might not be 
associated with persistent disease. The cytological 
differential diagnosis of borderline/ASCUS changes 
is often moderate dykaryosis/HSIL rather than low 
grade dyskaryosis/LSIL (cases of borderline, atypical 
squamous cells, cannot rule out high grade squamous 
intraepithelial lesion (ASCH) are reported but not 
recorded separately). Also, changes have occurred 
in the classification of HPV related cytological 
changes, and the management of CIN grade 1 or less 
at colposcopy that will have affected the relation 
between low grade cytology and a diagnosis of CIN 
grade 1.
Strengths and limitations of this study
The strengths of this study include direct linkage of 
data between immunisation status and screening 
outcomes, and that the data are from the screened 
population rather than a selected cohort. The 
completeness of the screening database and the 
longstanding, organised nature of the surveillance 
programme means that it is possible to show trends 
and to examine their correlation to several variables. 
The data therefore form a sound basis for development 
of cervical cancer prevention strategies.
This study has limitations. The analysis was 
confined to women attending for cervical screening at 
age 20. Uptake of screening in fully vaccinated women 
aged 20 or 21 is 51%, and only 23% in unvaccinated 
women.14 18 It is possible therefore that vaccine 
effectiveness was over-estimated. However, the high 
uptake of vaccination, similarity in distribution 
of HPV type in attenders and non-attenders, and 
appearance of herd protection give reassurance that 
the observations can be extrapolated to the general 
population.19
The shorter follow-up time for women born in 
1995 and 1996 necessarily affects the robustness of 
the estimation of vaccine effectiveness for younger 
women; however, further planned longitudinal 
studies will help elucidate true protection from the 
effects of routine vaccination. The formal adoption 
of a conservative management protocol for women 
with CIN grade 1 at colposcopy over the study period 
could have affected the numbers of biopsies carried 
out. However, it is unlikely that this change in practice 
accounted for the magnitude of the reductions in CIN 
grade 1, particularly when considered along with the 
reductions in CIN grades 2 and 3, for which there were 
no changes in clinical management or treatment over 
the study period.
CIN grade 3 is now considered the best predictor of 
risk of invasive cancer, but a proportion will still regress. 
It is known that the likelihood of developing CIN grade 
3 varies with the HPV genotype and is highest with 
HPV types 16, 31, and 33.20 The propensity for the CIN 
to regress is also related to the HPV type, and there are 
fewer cancers attributable to HPV type 33 than would 
be expected from the prevalence of this genotype in 
CIN grade 3 lesions.21 As the most oncogenic types 
have been effectively removed from the population it 
might be that regression of CIN grade 3 is more likely in 
vaccinated women, increasing vaccine effect on rates 
of CIN grade 3.
Another unavoidable limitation of high compliance 
with full vaccine schedules is the inability to assess the 
impact of fewer than three doses. The characteristics 
of partially immunised women in Scotland have been 
described previously.5 Briefly, partial immunisation 
was associated with increased deprivation, having left 
school, and increasing age. In girls offered routine, 
in-school vaccination, only 1.6% were partially 
immunised compared with 9.8% in the first full year 
of catch-up.
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Fig 3 | Histological abnormality (% of women screened) by year of birth and 
immunisation status. Whiskers represent 95% confidence intervals. CIN=cervical 
intraepithelial neoplasia; 1988-90=pre-immunisation programme cohort; 
1991-94=catch-up cohort; 1995-96=routinely immunised cohort
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Comparison with other studies
These results are the clinical counterpart of the 
reductions in type specific HPV infection shown 
in routinely vaccinated women.12 Kavanagh and 
colleagues showed statistically significant vaccine 
effectiveness against HPV types 16 and 18 (90%) 
and cross protective HPV types (80-85%), with cross 
protection lasting a minimum of seven years. Herd 
protection against HPV 16 and 18 related infection 
was also found in unvaccinated women in the routine 
vaccination cohort. The reduction of CIN grade 3 and 
the estimates of vaccine effectiveness reported are of a 
similar magnitude to those reported by Kavanagh and 
colleagues for HPV infection.12 The vaccine specific 
and cross protected HPV types covered by the vaccine 
(HPV 16, 18, 31, 33, and 45) are implicated in 90% of 
cancers in Scotland.22 CIN grade 3 is the precursor of 
invasive cervical carcinoma, with the least diagnostic 
variability and lowest rate of spontaneous regression, 
and it is recognised as the best indicator of the risk 
of invasive cancer.23-25 It is therefore reasonable to 
expect that the reduction in CIN grade 3 will lead to 
a reduction in cervical cancer in future years. The 
anticipated impact of immunisation on cancer will 
take more time to become apparent.
A recent Cochrane review of the effectiveness 
of bivalent and quadrivalent HPV vaccination in 
randomised trials has shown unequivocal, high 
quality evidence of the benefits of immunisation.26 
Our results are in keeping with this review. Population 
studies in other settings have shown a major impact of 
the quadrivalent vaccine on infection and associated 
benign and neoplastic disease.27-34 The present work 
complements these studies in being the first to report 
on the impact of the bivalent vaccine on disease when 
delivered to girls aged 12-13 years within a national 
programme. It will now be of interest to see the impact 
of the nonavalent vaccine at the population level. It 
is postulated that the nonavalent vaccine will protect 
against 90% of cervical cancers globally.35 However, 
worthwhile additional protection against cancer 
because of the nonavalent vaccine will be difficult 
to show in Scotland, given the distribution of HPV 
types in the UK, the effect of the bivalent vaccine, and 
the absence of type replacement to date, although 
the effect on genital warts is clear.27 The Scottish 
cervical screening programme is incorporating HPV 
immunisation into its routine programme monitoring 
statistics. This, along with the projected move to HPV 
primary screening, will facilitate the monitoring of 
changes in vaccine effectiveness in the future.
Policy implications
Low levels of cervical cancer after routine vaccination 
clearly have ramifications for screening vaccinated 
women. Although major disease is reduced in Scotland, 
it has not been eradicated, and continued screening 
is therefore necessary, particularly as for some years 
most women within the screening programme will not 
have been vaccinated. Previous work has suggested 
that the performance of cytology based and HPV based 
screening deteriorates in vaccinated women, despite 
preservation of sensitivity.7 8 This can be attributed to 
reduced disease levels leading to a higher number of 
false positive test results and a lower positive predictive 
value for important disease. The effectiveness of HPV 
primary screening in highly immunised populations 
will need close monitoring. Novel methods for 
improving uptake of screening, the effectiveness 
of the screening and, crucially, the triage test will 
be needed to maintain the performance of cervical 
screening as a process. The reduced rate of disease in 
those referred for colposcopy will likewise make the 
maintenance of colposcopy standards challenging.10 
11 Different modelling approaches have been used to 
inform optimal scenarios for screening of vaccinated 
women but have converged on the conclusion that, for 
some women, two or three screens in a lifetime using 
HPV testing might be sufficient.36 37 Such sporadic 
screening, coupled with much reduced disease and 
decreasing numbers of women referred for colposcopy 
and treatment, necessitates redesign of cervical 
screening programmes. Ultimately, the clinical and 
economic rationale for cervical screening will need to 
be reviewed.
Conclusion
We have presented linked data, from a population with 
high vaccine uptake and a comprehensive catch-up 
programme, which show routine immunisation with 
three doses of bivalent vaccine at age 12-13 years 
is associated with a profound reduction of cervical 
disease seven years later, measured by cytological and 
histological abnormalities and referral for colposcopy. 
Disease was also reduced in unvaccinated women, 
possibly because of herd protection. Routinely 
vaccinated populations will also have a lower risk of 
other HPV related diseases.38 The reduction in disease 
in routinely immunised women, who will form the bulk 
of the screened population in years to come, mandates 
revision of screening and referral guidelines. The 
findings emphasise the credibility of using high risk 
HPV infection as an early marker of the effectiveness 
and success of the vaccine and underpin the recent 
call for global action on cervical cancer from the World 
Health Organization.
The manuscript was reviewed by Jo’s Trust, which supports the 
conclusions. It made the following statement: We think (it has) 
massive implications for the screening programme, vaccine and 
also impact on diagnoses in the future. It gives weight for activity 
to increase vaccine uptake, has implications on screening intervals. 
The clinically relevant herd protection is very interesting too. It also 
feeds into our policy calls for a new IT infrastructure (for the screening 
programme in England) to record and enable invitations based on 
whether someone has at the vaccine if intervals can be extended.
Contributors: TP was the lead author, conducted the literature search, 
produced the initial drafts, and collated comments. He specified the 
data extracted and worked with LW, CR, and the Cervical Screening 
system managers to confirm the quality of the extracted data. TP is 
the guarantor for this study. LW undertook the data analysis under the 
guidance of CR and reviewed early drafts. CR directed the statistical 
analysis and reviewed successive drafts. KC and KP provided support 
with analysis or interpretation, contextualisation, and generation 
of manuscript drafts. KK and MC provided additional statistical and 
clinical input and reviewed the later drafts. The corresponding author 
 o
n
 18 April 2019 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.l1161 on 3 April 2019. Downloaded from 
RESEARCH
the bmj | BMJ 2019;365:l1161 | doi: 10.1136/bmj.l1161 9
attests that all listed authors meet authorship criteria and that no 
others meeting the criteria have been omitted.
Funding: This study has been undertaken as part of the programme 
of surveillance of immunisation against human papillomavirus in 
Scotland, included within the routine work of Health Protection 
Scotland, a part of the Scottish National Health Service. No funding 
has been received from industry.
Competing interests: All authors have completed the ICMJE uniform 
disclosure form at www.icmje.org/coi_disclosure.pdf and declare: 
KP has received travel monies from both Merck and GSK to attend 
conferences. KC’s institution has received monies to deliver research, 
or associated consumables to support research, from: Qiagen, 
Hologic, Selfscreen, GeneFirst, Euroimmun, Cepheid, Genomica, and 
LifeRiver. No personal conflicts of interest are declared.
Ethical approval: No ethical approval was required for this study 
as patient treatment was not altered by the observations. Caldicott 
approval for use of personal data was obtained.
Data sharing: No additional data available.
Transparency: The manuscript’s guarantor (TP) affirms that this 
manuscript is an honest, accurate, and transparent account of the 
study being reported; that no important aspects of the study have 
been omitted; and that any discrepancies from the study as planned 
(and, if relevant, registered) have been explained.
This is an Open Access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, 
which permits others to distribute, remix, adapt, build upon this work 
non-commercially, and license their derivative works on different 
terms, provided the original work is properly cited and the use is non-
commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
1  GLOBOCAN Cervical cancer fact sheet. http://globocan.iarc.fr/Pages/
fact_sheets_cancer.aspx.
2  Mercer CH, Tanton C, Prah P, et al. Changes in sexual attitudes and 
lifestyles in Britain through the life course and over time: findings 
from the National Surveys of Sexual Attitudes and Lifestyles (Natsal). 
Lancet 2013;382:1781-94. doi:10.1016/S0140-6736(13)62035-
8 
3  Cancer Research UK. www.cancerresearchuk.org/health-professional/
cancer-statistics/statistics-by-cancer-type/cervical-cancer/diagnosis-
and-treatment#heading-Eight.
4  Information Services Division. Scotland. Estimate of HPV vaccine 
uptake in Scotland, by year of birth. https://isdscotland.scot.nhs.
uk/Health-Topics/Child-Health/publications/data-tables2017.
asp?id=2048#2048.
5  Sinka K, Kavanagh K, Gordon R, et al. Achieving high and equitable 
coverage of adolescent HPV vaccine in Scotland. J Epidemiol 
Community Health 2014;68:57-63. doi:10.1136/jech-2013-
202620 
6  Pollock KG, Kavanagh K, Potts A, et al. Reduction of low- and high-
grade cervical abnormalities associated with high uptake of the 
HPV bivalent vaccine in Scotland. Br J Cancer 2014;111:1824-30. 
doi:10.1038/bjc.2014.479 
7  Palmer TJ, McFadden M, Pollock KG, et al. HPV immunisation and 
cervical screening--confirmation of changed performance of cytology 
as a screening test in immunised women: a retrospective population-
based cohort study. Br J Cancer 2016;114:582-9. doi:10.1038/
bjc.2015.474 
8  Bhatia R, Kavanagh K, Cubie HA, et al. Use of HPV testing for 
cervical screening in vaccinated women--Insights from the SHEVa 
(Scottish HPV Prevalence in Vaccinated Women) study. Int J 
Cancer 2016;138:2922-31. doi:10.1002/ijc.30030 
9  Kavanagh K, Pollock KG, Potts A, et al. Introduction and sustained 
high coverage of the HPV bivalent vaccine leads to a reduction 
in prevalence of HPV 16/18 and closely related HPV types. Br J 
Cancer 2014;110:2804-11. doi:10.1038/bjc.2014.198 
10  Cruickshank ME, Pan J, Cotton SC, et al. Reduction in colposcopy 
workload and associated clinical activity following human 
papillomavirus (HPV) catch-up vaccination programme in Scotland: 
an ecological study. BJOG 2017;124:1386-93. doi:10.1111/1471-
0528.14562 
11  Munro A, Gillespie C, Cotton S, et al. The impact of human 
papillomavirus type on colposcopy performance in women 
offered HPV immunisation in a catch-up vaccine programme: 
a two-centre observational study. BJOG 2017;124:1394-401. 
doi:10.1111/1471-0528.14563 
12  Kavanagh K, Pollock KG, Cuschieri K, et al. Changes in the prevalence 
of human papillomavirus following a national bivalent human 
papillomavirus vaccination programme in Scotland: a 7-year cross-
sectional study. Lancet Infect Dis 2017;17:1293-302. doi:10.1016/
S1473-3099(17)30468-1 
13  Donken R, King AJ, Bogaards JA, Woestenberg PJ, Meijer CJLM, de 
Melker HE. High Effectiveness of the Bivalent Human Papillomavirus 
(HPV) Vaccine Against Incident and Persistent HPV Infections 
up to 6 Years After Vaccination in Young Dutch Women. J Infect 
Dis 2018;217:1579-89. doi:10.1093/infdis/jiy067 
14  Information Services Division. Scotland. www.isdscotland.org/Health-
Topics/Cancer/Cervical-Screening/.
15  Denton K. The proposed BSCC terminology for abnormal cervical 
cytology. Cytopathology 2008;19:398-9. doi:10.1111/j.1365-
2303.2008.00624.x 
16  Colposcopy and programme management: guidelines for the 
NHS CervicalScreening Programme. NHS CSP Document 20. 2nd 
edn (2010) www.cancerscreening.nhs.uk/cervical/publications/
nhscsp20.html.
17  Nayar R, Wilbur DC. The Pap Test and Bethesda 2014. “The reports of 
my demise have been greatly exaggerated.” (after a quotation from 
Mark Twain). Acta Cytol 2015;59:121-32. doi:10.1159/000381842 
18  Palmer TJ, McFadden M, Pollock KG, et al. HPV immunisation 
and increased uptake of cervical screening in Scottish women; 
observational study of routinely collected national data. Br J 
Cancer 2016;114:576-81. doi:10.1038/bjc.2015.473 
19  Kavanagh K, Sinka K, Cuschieri K, et al. Estimation of HPV prevalence 
in young women in Scotland; monitoring of future vaccine impact. 
BMC Infect Dis 2013;13:519. doi:10.1186/1471-2334-13-519 
20  Cuzick J, Wheeler C. Need for expanded HPV genotyping for cervical 
screening. Papillomavirus Res 2016;2:112-5. 
21  Carcopino X, Bolger N, Henry M, et al. Evaluation of type-specific 
HPV persistence and high-risk HPV viral load quantitation in HPV 
positive women under 30 with normal cervical cytology. J Med 
Virol 2011;83:637-43. doi:10.1002/jmv.22022 
22  Mesher D, Cuschieri K, Hibbitts S, et al. Type-specific HPV 
prevalence in invasive cervical cancer in the UK prior to national 
HPV immunisation programme: baseline for monitoring the effects 
of immunisation. J Clin Pathol 2015;68:135-40. doi:10.1136/
jclinpath-2014-202681 
23  Carreon JD, Sherman ME, Guillén D, et al. CIN2 is a much 
less reproducible and less valid diagnosis than CIN3: results 
from a histological review of population-based cervical 
samples. Int J Gynecol Pathol 2007;26:441-6. doi:10.1097/
pgp.0b013e31805152ab 
24  Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence 
for frequent regression of cervical intraepithelial neoplasia-
grade 2. Obstet Gynecol 2009;113:18-25. doi:10.1097/
AOG.0b013e31818f5008 
25  Lee MH, Finlayson SJ, Gukova K, Hanley G, Miller D, Sadownik LA. 
Outcomes of Conservative Management of High Grade Squamous 
Intraepithelial Lesions in Young Women. J Low Genit Tract 
Dis 2018;22:212-8. doi:10.1097/LGT.0000000000000399 
26  Arbyn M, Xu L, Simoens C, Martin-Hirsch PP. Prophylactic vaccination 
against human papillomaviruses to prevent cervical cancer and its 
precursors. Cochrane Database Syst Rev 2018;5:CD009069.
27  Garland SM, Kjaer SK, Muñoz N, et al. Impact and Effectiveness of the 
Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 
10 Years of Real-world Experience. Clin Infect Dis 2016;63:519-27. 
doi:10.1093/cid/ciw354 
28  Herweijer E, Sundström K, Ploner A, Uhnoo I, Sparén P, Arnheim-
Dahlström L. Quadrivalent HPV vaccine effectiveness against 
high-grade cervical lesions by age at vaccination: A population-based 
study. Int J Cancer 2016;138:2867-74. doi:10.1002/ijc.30035 
29  Hariri S, Markowitz LE, Bennett NM, et al, Hpv-Impact Working 
Group. Monitoring Effect of Human Papillomavirus Vaccines in US 
Population, Emerging Infections Program, 2008-2012. Emerg Infect 
Dis 2015;21:1557-61. doi:10.3201/eid2109.141841 
30  Smith LM, Strumpf EC, Kaufman JS, Lofters A, Schwandt M, Lévesque 
LE. The early benefits of human papillomavirus vaccination on 
cervical dysplasia and anogenital warts. Pediatrics 2015;135:e1131-
40. doi:10.1542/peds.2014-2961 
31  Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer SK. Early impact 
of human papillomavirus vaccination on cervical neoplasia--
nationwide follow-up of young Danish women. J Natl Cancer 
Inst 2014;106:djt460. doi:10.1093/jnci/djt460 
32  Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville 
AM. Impact of a population-based HPV vaccination program on 
cervical abnormalities: a data linkage study. BMC Med 2013;11:227. 
doi:10.1186/1741-7015-11-227 
33  Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, 
Gertig DM. Early effect of the HPV vaccination programme 
on cervical abnormalities in Victoria, Australia: an ecological 
study. Lancet 2011;377:2085-92. doi:10.1016/S0140-
6736(11)60551-5 
34  Niccolai LM, Julian PJ, Meek JI, McBride V, Hadler JL, Sosa LE. Declining 
rates of high-grade cervical lesions in young women in Connecticut, 
2008-2011. Cancer Epidemiol Biomarkers Prev 2013;22:1446-50. 
doi:10.1158/1055-9965.EPI-13-0272 
 o
n
 18 April 2019 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.l1161 on 3 April 2019. Downloaded from 
RESEARCH
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
35  Luckett R, Feldman S. Impact of 2-, 4- and 9-valent HPV vaccines 
on morbidity and mortality from cervical cancer. Hum Vaccin 
Immunother 2016;12:1332-42. doi:10.1080/21645515.2015.11
08500
36  Lew JB, Simms KT, Smith MA, et al. Primary HPV testing versus 
cytology-based cervical screening in women in Australia vaccinated 
for HPV and unvaccinated: effectiveness and economic assessment 
for the National Cervical Screening Program. Lancet Public 
Health 2017;2:e96-107. doi:10.1016/S2468-2667(17)30007-5 
37  Kim JJ, Burger EA, Sy S, Campos NG. Optimal Cervical Cancer 
Screening in Women Vaccinated Against Human Papillomavirus. J 
Natl Cancer Inst 2016;109:djw216. doi:10.1093/jnci/djw216 
38  Pan J, Kavanagh K, Cuschieri K, et al. Increased risk of HPV-associated 
genital cancers in men and women as a consequence of pre-invasive 
disease. IJC, 2018. https://doi.org/10.1002/ijc.3212. 
Supplementary table: Distribution of vaccination 
status and cytology and histology results by year of birth
 o
n
 18 April 2019 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.l1161 on 3 April 2019. Downloaded from 
